CSL Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares CSL Limited with three other
companies in this sector in UNITED STATES :
sales of $3.09 billion
of which 34%
was Softgel and Oral Technologies),
Daiichi Sankyo Company Limited
of which 93%
was Prescription drugs), and
Eisai Company Limited
of which 83%
was Pharmaceutical Business).
CSL Limited reported sales of $9.15 billion
June of 2020.
increase of 7.2%
versus 2019, when the company's sales were $8.54 billion.
Sales at CSL Limited have increased during each of the previous five years
(and since 2015, sales have increased a total of 63%).
Sales of Seqirus saw an increase
11.5% in 2020, from
$1.02 billion to $1.14 billion.